Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsGlobeNewsWire • Wednesday
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 MilestoneSeeking Alpha • 03/19/24
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsGlobeNewsWire • 03/14/24
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsGlobeNewsWire • 03/11/24
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningNewsfile Corp • 03/06/24
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024GlobeNewsWire • 03/05/24
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/01/24
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerGlobeNewsWire • 02/20/24
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsGlobeNewsWire • 12/12/23
Immuneering to Present at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/20/23
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC ConferenceGlobeNewsWire • 10/12/23
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/04/23
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/03/23
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a BetZacks Investment Research • 07/05/23
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid TumorsGlobeNewsWire • 06/05/23
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/23